Neurotrek is developing U+, a targeted, non-invasive neuromodulation technology to optimize cognitive abilities and experiences in healthy individuals, as well as create a powerful platform for several important therapies; long term goals for the product include the improvement of mental health and well-being. The company is engaged in early-stage development of both consumer-grade and clinical-grade products based on this core technology. Neuromodulation technologies such as transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS) have been demonstrated to enhance cognitive abilities such as creativity, working memory, and accelerated learning. TDCS and TMS use electrical and magnetic energy to stimulate brain regions and have been shown to induce positive effects in cognitive-based skills as well as mood. U+ has the potential to also optimize cognitive abilities and to do so more reliably and selectively due to the targeted nature of the product and the greater flexibility it offers over stimulus parameters. In addition, there are applications that would optimize emotional and physiological responses as well as enable direct communication between individuals.
